Heidelberg Epignostix GmbH
Heidelberg Epignostix GmbH is a deeptech start-up established in 2022, focused on improving cancer diagnostics through DNA methylation profiling and machine learning. The company develops, certifies, and markets software solutions for molecular tumor classification. Their vision is to enable precise and personalized cancer treatments by providing accurate diagnostic tools. They offer classifiers for CNS tumors and sarcomas, with more in the pipeline. The team comprises experts in genetics, pathology, data science, and AI. Their solutions aim to assist healthcare professionals, researchers, and pharmaceutical companies in understanding tumor subtypes and improving patient outcomes.
Heidelberg Epignostix GmbH
Heidelberg Epignostix GmbH is a deeptech start-up established in 2022, focused on improving cancer diagnostics through DNA methylation profiling and machine learning. The company develops, certifies, and markets software solutions for molecular tumor classification. Their vision is to enable precise and personalized cancer treatments by providing accurate diagnostic tools. They offer classifiers for CNS tumors and sarcomas, with more in the pipeline. The team comprises experts in genetics, pathology, data science, and AI. Their solutions aim to assist healthcare professionals, researchers, and pharmaceutical companies in understanding tumor subtypes and improving patient outcomes.
TL;DR
Founded: 2022 (Heidelberg, Germany)
Focus: DNA methylation + AI tumour classification software
Lead products: CNS (brain) and sarcoma methylation classifiers
Seed funding: €4.3M (July 2, 2024)
Team size (approx.): 13 employees
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Cancer diagnostics — molecular tumour classification using DNA methylation profiling and AI.
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
€4.3M
Participation from High-Tech Gründerfonds (HTGF), LBBW Venture Capital, and Start-up BW Seed Fonds
Investor Signal
“Led by a specialist life-sciences investor (CARMA FUND I) with participation from notable German seed investors”